SMAD4 Antikörper (AA 100-300)

Produktnummer ABIN7869860

Dieser Maus Monoklonal Antikörper detektiert spezifisch SMAD4 in IHC (p). Es zeigt Reaktivität gegenüber Proben von Human.

Kurzübersicht für SMAD4 Antikörper (AA 100-300) (ABIN7869860)

Target: SMAD4 (SMAD Family Member 4 (SMAD4))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser SMAD4 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: SMAD4-7903

Produktdetails anti-SMAD4 Antikörper

Bindungsspezifität: AA 100-300

Verwendungszweck: SMAD4 Antibody (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: A recombinant partial protein sequence (within amino acids 100-300) from the human protein was used as the immunogen for the SMAD4 antibody.

Isotyp: IgG2, lambda

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the SMAD4 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Aliquot the SMAD4 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu SMAD4

Target: SMAD4 (SMAD Family Member 4 (SMAD4))

Andere Bezeichnung: SMAD4

Hintergrund: Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4.Upon ligand binding, the receptors of the TGF-beta family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80 % of cases of pancreatic adenocarcinoma, but rarely in endometrial (0 %), colorectal (0 %), ovarian (3 %), lung (0 %), breast (2 %) adenocarcinomas, and malignant melanoma (4 %). SMAD4is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.

UniProt: Q13485

Pathways: Zellzyklus, Chromatin Binding, Autophagie